1. 8 stocks that remain in focus in Thursday’s trade: Natco Pharma, Welspun India and more

8 stocks that remain in focus in Thursday’s trade: Natco Pharma, Welspun India and more

Jubilant Life Sciences stocks ended 4.63 per cent up at Rs 530.55 after the company announced that it has received Abbreviated New Drug Application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil Tablets of AstraZeneca, which is used for the treatment of hypertension.

By: | Updated: August 25, 2016 5:42 PM
Stocks in focus today Jubilant Life Sciences stocks ended 4.63 per cent up at Rs 530.55 after the company announced that it has received Abbreviated New Drug Application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil Tablets of AstraZeneca, which is used for the treatment of hypertension. (Express photo)

The BSE Sensex and NSE Nifty reversed their early morning gains and closed lower on Thursday following profit booking amid weak opening at European markets. Investors also remained cautious today on August F&O expiry.  Sensex closed 224.03 points down to settle at 27,835.91, while NSE Nifty slumped 58.10 points to end at 8,592.20.

Below are the 8 stocks that are in focus today

Inox Leisure: Share price of the company ended 5.76 per cent up at Rs 275.30 after as it plans to invest Rs 200 crore to add up to 60 cinema screens across the country this fiscal.

Monsanto India: Stocks of the company closed 2.78 per cent down at Rs 2368.90 as its parent company has withdrawn an application seeking approval for its next generation of genetically modified cotton seeds in India, a major escalation in a long-running dispute between New Delhi and the world’s biggest seed maker.

PNC Infratech: Stocks of the company closed 0.70 per cent up at Rs 121.90 after its consolidated net profit more than doubled for the quarter ended June 30, to Rs 54.20 crore as against net profit of Rs 22.13 crore in the year-ago period.

Natco Pharma: Natco Pharma shares hit their fresh 52-week high of Rs 703.95 on Thursday after it said that it has received a successful Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted, from February 8 to February 12, 2016, at its Chemical Division in Chennai (named Natco Organics, prior to amalgamation into the company). In another news, the US Patent and Trademark Office has ruled in favour of its marketing partner Mylan by invalidating two of Israel-based Teva Pharmaceuticals’ patents related to multiple sclerosis drug Copaxone 40 mg/mL.

Welspun India: Welspun India shares ended 8.26 per cent down at Rs 54.40 after staging a recovery following media reports said that after Walmart, JC Penny, another big US retail giant Bed Bath & Beyond has ordered an external audit of the textile company in the wake of Target Corp terminating business ties with the Gujarat-based firm textiles over use of low quality cotton.

Jubilant Life Sciences: Stocks of the company ended 4.63 per cent up at Rs 530.55 after the company announced that it has received Abbreviated New Drug Application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil Tablets of AstraZeneca, which is used for the treatment of hypertension.

Ramco Systems: Stocks of the company ended 1.26 per cent up at Rs 520 after it has informed BSE that company’s subsidiary, Ramco Systems Pte Ltd., Singapore, has secured order from one of the top 5 most valuable global brands for Ramco HCM & Payroll in APAC.

Nava Bharat Ventures: Stocks of the company ended 2.63 per cent up at Rs 245.65 after the company entered into a sale and purchase agreement to sell 100 per cent equity stake in Nava Bharat Lao Energy (NBLE – wholly owned subsidiary of NBS) and thereby its 70 per cent equity stake in Namphak Power Company, which has been developing the 150 MW hydro power project in Lao PDR, in two tranches.

  1. No Comments.

Go to Top